News & events

Cannabis-based medicine to be tested in Alzheimer's trial

Researchers from the NIHR Maudsley BRC are to lead a pioneering new study into a cannabis-based treatment for people living with dementia. Alzheimer’s Research UK has awarded over £250,000 for the landmark phase II clinical trial of Sativex®, a cannabis-based medicine licenced in the UK. The drug has already been found to be safe in people and has been approved for use in the treatment of muscle stiffness and tightness experienced by people with multiple sclerosis. However, Sativex® is not currently licensed in the UK for any other indication, including treatment of the symptoms of dementia.

 

By NIHR Maudsley BRC at 21 Feb 2019

Could intranasal oxytocin be used to treat people at clinically high risk of psychosis?

Oxytocin, a hormone most often associated with childbirth, is also known for its effects on social-emotional cognition and behaviour. According to new research supported by the NIHR Maudsley BRC, oxytocin also alters blood flow in the hippocampus — a brain region strongly implicated in the onset of psychosis — in those at clinically high risk of psychosis.

By NIHR Maudsley BRC at 12 Feb 2019

Top mental health trust in England for number of research studies

South London and Maudsley NHS Foundation Trust was the top mental health trust in the country for the number of open studies last year with 101 studies available for patients to participate in. This was up by 14 per cent from 89 studies the previous year. This is according to new figures from the National Institute for Health Research (NIHR).

By NIHR Maudsley BRC at 18 Jul 2018

Exploring a new approach for people with Alzheimer’s disease

King's College London part of major new research project exploring role of immune cells in Alzheimer's Disease.

By NIHR Maudsley BRC at 11 Jan 2017

Research blog Trialling an online tool to help women make decisions about antidepressants in pregnancy

A new tool to help pregnant women make decisions about antidepressant medication is being developed and tested.

By NIHR Maudsley BRC at 29 Jun 2016